Hermab 150 mg Injection contains trastuzumab, a monoclonal antibody. It is mainly used to treat HER2-positive breast cancer and HER2-positive gastric (stomach) cancer. This medicine works by specifically targeting the HER2 (human epidermal growth factor receptor-2) protein, which is present in higher amounts on the surface of certain cancer cells.
HER2 is a receptor found on the surface of normal cells that helps regulate cell growth and division. However, in some cancers, this receptor is produced in excess. When HER2 is overexpressed, it can cause cells to grow and multiply uncontrollably, leading to the development and progression of cancer. Hermab contains trastuzumab, which binds to the outer part of the HER2 receptor and blocks its activity. By doing so, it interrupts the signals that encourage cancer cells to grow and survive, helping slow down or stop the spread of the disease.
Hermab 150mg Injection works by attaching directly to the HER2 receptors on cancer cells. This targeted action helps prevent the rapid growth and replication of these cells and allows the immune system to better identify and destroy them. Because it is a targeted therapy, it focuses mainly on cancer cells with the HER2 protein, which makes it an important treatment option for patients with HER2-positive cancers.
Like many cancer treatments, Hermab may cause certain side effects. Some commonly reported side effects include fever, cough, headache, rash, infections, and sleep disturbances. In some cases, more serious side effects may occur, such as heart-related problems, allergic reactions, or lung complications. Due to potential risks to the unborn baby, this medicine is generally not recommended during pregnancy, and patients should discuss contraception and pregnancy planning with their doctor before starting treatment.
Hermab 150mg Injection is administered as an intravenous (IV) infusion by a trained healthcare professional in a clinical setting. Depending on the treatment plan and the patient’s condition, it may be given once every week or once every three weeks. Before administration, the powder form of the medicine is carefully reconstituted and diluted under sterile conditions. In some cases, doctors may give pre-medication to help reduce infusion-related reactions. During treatment, patients are closely monitored, including checks of heart function and vital signs, to ensure safety. This medication should never be self-administered and must always be given under medical supervision.
Hermab 150mg Injection is primarily used to treat HER2-positive cancers, where cancer cells produce an excess amount of the HER2 protein.
This targeted therapy works by blocking HER2 receptors on cancer cells, helping slow their growth and supporting the immune system in destroying them.
Hermab 150mg Injection is a biosimilar of trastuzumab that targets the HER2 (Human Epidermal Growth Factor Receptor-2) protein found in high amounts on certain cancer cells. As a monoclonal antibody, it attaches to the HER2 receptor and blocks the signals that promote cancer cell growth and survival. By doing this, it slows the growth of HER2-positive cancer cells and also helps the immune system recognize and destroy them, which helps control the progression of the cancer.
Side Effects of Hermab 150mg Injection
Like all medications, Hermab 150mg Injection may cause side effects. However, not everyone will experience them.
Serious Side Effects (Seek immediate medical attention):
Common Side Effects (Usually mild and temporary):
Hermab 150mg (Trastuzumab) is administered as an intravenous (IV) infusion by a qualified healthcare professional experienced in cancer treatment. The therapy usually begins with a loading dose of 8 mg/kg, given slowly over about 90 minutes while the patient is closely monitored for any reactions. This is followed by a maintenance dose of 6 mg/kg every 3 weeks (21-day cycle), typically infused over 30–90 minutes depending on patient tolerance. The dose is calculated based on the patient’s actual body weight, and the medicine should never be given as a rapid injection. If serious infusion reactions or heart-related issues occur, the doctor may adjust or delay the treatment according to the patient’s condition.
Hermab 150mg may pass into breast milk and could harm the baby. Breastfeeding is not recommended during treatment, so consult your doctor before starting or stopping breastfeeding.
Drinking alcohol during treatment may increase certain side effects. It is best to speak with your doctor about safe alcohol consumption while receiving Hermab.
Patients with serious lung conditions or those requiring oxygen support should use this medicine with caution. Inform your doctor if you experience breathing difficulties or lung-related symptoms.
Hermab may cause fatigue, dizziness, or weakness in some patients. Avoid driving or operating heavy machinery if you feel unwell after receiving the infusion.
Hermab 150mg Injection should not be used during pregnancy as it may harm the unborn baby. Women who can become pregnant should use effective contraception during treatment and for at least 7 months after the last dose. Inform your doctor immediately if pregnancy occurs during treatment.
Hermab150mg is a targeted therapy that specifically attacks cancer cells with the HER2 protein. Unlike chemotherapy, which affects both healthy and cancer cells, Hermab blocks HER2 signals and helps the immune system destroy cancer cells.
Most side effects are temporary and improve after treatment. However, some effects, especially heart or lung-related issues, may require long-term monitoring.
If you miss a dose, contact your doctor immediately. Do not take a double dose or try to administer it yourself.
There are no known food restrictions, but limiting alcohol and excessive caffeine is recommended during treatment.
Hermab 150mg may interact with some chemotherapy medicines like paclitaxel or carboplatin, which can increase certain side effects. Always inform your doctor about all medications you take.
Yes, Hermab 150mg may cause heart-related problems in some patients. Doctors usually monitor heart function regularly during treatment.
| Active ingredient | Trastuzumab |
| Pharmacologic class | Recombinant IgG1 monoclonal antibody |
| Medication category | ANTI NEOPLASTICS |
| Dosage forms | Injection |
The information on the Phoenix Pharmex website is shared for educational purposes only and is not a substitute for professional medical advice or treatment. Always consult a doctor for any health-related questions. Please avoid self diagnosis or delaying medical care based on this content. Our mission is to support informed decisions not replace professional medical guidance.
Life-Saving Medicines Expert
Affordable Patient-Centered Care
Authentic, Top-Quality Medicines
Careful & Timely Medicine Deliveries
Login with Facebook
Login with Google
